Redmile Group VERV Position
Exited7-Fund ConvergenceRedmile Group exited their position in Verve Therapeutics Inc. (VERV) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
VERV is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Verve Therapeutics Inc.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Full company profile →Redmile Group VERV Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -740,261 | $0 |
| Q2 2025 | Decreased | 740,261 | -466,903 | $8.3M |
| Q1 2025 | Decreased | 1,207,164 | -111,000 | $5.5M |
| Q4 2024 | Decreased | 1,318,164 | -65,202 | $7.4M |
| Q3 2024 | Decreased | 1,383,366 | -80,040 | $6.7M |
| Q2 2024 | Decreased | 1,463,406 | -141,109 | $7.1M |
| Q1 2024 | Decreased | 1,604,515 | -114,154 | $21.3M |
| Q4 2023 | Increased | 1,718,669 | +908,892 | $24.0M |
| Q3 2023 | Decreased | 809,777 | -252,183 | $10.7M |
| Q2 2023 | Decreased | 1,061,960 | -58,719 | $19.9M |
| Q1 2023 | New | 1,120,679 | +1,120,679 | $16.2M |
Frequently Asked Questions
Does Redmile Group own VERV?
No. Redmile Group exited their position in Verve Therapeutics Inc. (VERV) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own VERV?
7 specialist biotech hedge funds currently hold VERV, including Casdin Capital, BVF Partners, Baker Bros. Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Redmile Group first buy VERV?
Redmile Group's position in VERV was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Redmile Group's VERV position increasing or decreasing?
Redmile Group completely exited their VERV position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VERVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Redmile GroupPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →